Clearstead Advisors’s Pliant Therapeutics PLRX Stock Holding History

Clearstead Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$54	–	2844
2025 Q1	$54	Hold	40	–	–	﹤0.01%	2160
2024 Q4	$527	Hold	40	–	–	﹤0.01%	1979
2024 Q3	$449	Hold	40	–	–	﹤0.01%	1962
2024 Q2	$430	Hold	40	–	–	﹤0.01%	1945
2024 Q1	$547	Hold	40	–	–	﹤0.01%	1451
2023 Q4	$725	Sell	40 -40	-50%	-$608	﹤0.01%	1431
2023 Q3	$1.39K	Buy	80 +40	+100%	+$693	﹤0.01%	1435
2023 Q2	$725	Hold	40	–	–	﹤0.01%	1278
2023 Q1	$1.06K	Hold	40	–	–	﹤0.01%	1232
2022 Q4	$773	Hold	40	–	–	﹤0.01%	1195
2022 Q3	$1K	Hold	40	–	–	﹤0.01%	1180
2022 Q2	$0	Hold	40	–	–	﹤0.01%	1402
2022 Q1	$0	Hold	40	–	–	﹤0.01%	1441
2021 Q4	$1K	Hold	40	–	–	﹤0.01%	1205
2021 Q3	$1K	Hold	40	–	–	﹤0.01%	1233
2021 Q2	$1K	Buy	+40	New	+$1.25K	﹤0.01%	1185

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Clearstead Advisors's PLRX Position: Q2 2025 in Review

Clearstead Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 40 shares — an estimated $54 sold.

Clearstead Advisors first reported a position in PLRX in Q2 2021 and held it in 16 quarters. The position peaked at $1.39K in Q3 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

Clearstead Advisors reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
Clearstead Advisors sold 40 Pliant Therapeutics shares in Q2 2025, an estimated $54.
Clearstead Advisors first reported a position in Pliant Therapeutics in Q2 2021 and held it in 16 quarters.
Clearstead Advisors's Pliant Therapeutics position peaked at $1.39K in Q3 2023.
114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Clearstead Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.